Ignite Creation Date:
2024-05-06 @ 1:37 AM
Last Modification Date:
2024-10-26 @ 11:07 AM
Study NCT ID:
NCT01854372
Status:
WITHDRAWN
Last Update Posted:
2013-12-10
First Post:
2013-05-10
Brief Title:
Rituximab-HyperCVAD R-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine- R-MC in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement
Sponsor:
The University of Texas Health Science Center at San Antonio
Organization:
The University of Texas Health Science Center at San Antonio
Study Overview
Official Title:
Rituximab-HyperCVAD R-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine- R-MC in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement A Phase 2 Multi-Center Open Label Study CTRC 11-53
Status:
WITHDRAWN
Status Verified Date:
2013-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To estimate the I-year progression-free survival probability in patients up to 70 years of age with previously untreated diffuse large B-celllymphoma DLBCL or with intermediate Burkitt-like lymphoma whose tumor cells show MYC rearrangement and who are treated with alternating cycles of Rituximab-HCV AD and Rituximab-Methotrexate-Cytarabine in concert with optimal supportive treatment including Pegfilgrastim prophylactic antimicrobials and close clinical follow-up
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None